Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.

Inclusion Criteria:

- Patients must have participated (been randomized) in the Copaxone Double-Blind placebo
controlled study (Protocol 01-9001).

- Gender: Patients may be male or female. Women of childbearing potential must practice
an acceptable method of birth control.

- Patients must sign an approved informed consent prior to initiating the study.

- Patients must be psychologically and physically stable to participate in the trial as
judged by the investigator.

Exclusion Criteria:

- Pregnancy or lactation.

- Medical or psychiatric conditions that affect the patient's ability to give informed
consent or complete the study.

- Inability to self-administer subcutaneous medication or lack of another responsible
individual to administer the study preparation daily.

- Use of Interferons, experimental MS therapies, or previous immunosuppressive therapy
with cytotoxic chemotherapy (azathioprine, cyclophosphamide, or cyclosporine), or
total lymphoid irradiation within 30 days of study entry.